What do systematic reviews say?

Minoxidil vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 304 participants
  Very low

Minoxidil vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Minoxidil vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 543 participants
  Very low

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone) +… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with contact immunotherapy (diphencyprone) (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 0.67 [0.13, 3.44]
  1 study · 30 participants
  Very low

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

It is very uncertain whether summary of findings table ‐ Intralesional classical… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 13.84 [0.87, 219.76]
  1 study · 231 participants
  Very low

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

The review found no eligible studies for this question.

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  No studies reported this outcome.
  0 studies
  No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

The review found no eligible studies for this question.

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  None of the included studies assessed the effectiveness of treatments of genital ELP; thus, this outcome was not reported.
  0 studies
  No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

The review found no eligible studies for this question.

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  No studies reported this outcome.
  0 studies
  No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

The review found no eligible studies for this question.

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  No studies reported this outcome.
  0 studies
  No studies found

Oral hydroxychloroquine vs placebo

Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 1.32 [0.24, 7.19]
  1 study · 47 participants
  Moderate

Oral dehydroepiandrosterone vs placebo

Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 10.5 [3.26, 33.75]
  1 study · 381 participants
  Moderate

Oral chloroquine vs placebo

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Oral ciclosporin vs azathioprine (AZA)

Oral ciclosporin may leads to higher adverse events: minor (hirsutism) compared with oral azathioprine (low certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 9.83 [1.32, 72.95]
  1 study · 89 participants
  Low

Oral methotrexate vs oral chloroquine

Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 3.9 [1.45, 10.51]
  1 study · 41 participants
  Low